14,670 Amgen Inc. $AMGN Shares Sold by Investment House LLC

Key Points

• Investment House LLC cut its Amgen stake by 58.5% in the third quarter, selling 14,670 shares and retaining 10,398 shares valued at approximately $4.38 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen shares rose 2.0% to $447.28, near a new 52-week high, while the company reported quarterly earnings and revenue above analyst expectations. Management also issued fiscal 2026 EPS guidance of $22.30–$23.50.
• The company paid a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 payout and a 2.3% yield. Despite several bullish analyst actions, the overall analyst consensus remains “Hold,” with a $388.64 average price target.

Investment House LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 58.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,398 shares of the medical research company's stock after selling 14,670 shares during the period. Investment House LLC's holdings in Amgen were worth $4,383,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. MW Advisory LLC bought a new position in Amgen in the second quarter valued at about $1,054,000. Baird Financial Group Inc. grew its holdings in shares of Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company's stock worth $123,057,000 after purchasing an additional 5,496 shares during the last quarter. Integrated Advisors Network LLC grew its holdings in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after purchasing an additional 6,356 shares during the last quarter. KBC Group NV grew its holdings in shares of Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company's stock worth $138,574,000 after purchasing an additional 130,497 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new position in shares of Amgen in the second quarter valued at approximately $3,329,000. Institutional investors own 76.50% of the company's stock.

Amgen Trading Up 2.0%

NASDAQ AMGN opened at $447.28 on Friday. The firm has a market capitalization of $241.81 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41. The business's 50-day moving average price is $417.22 and its two-hundred day moving average price is $377.39. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $450.98.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts expect that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio is currently 62.65%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Piper Sandler maintained a Buy rating and set a $457 price target, leaving additional upside from the stock’s latest 52-week high. Piper Sandler Remains a Buy on Amgen
• Positive Sentiment: Amgen reached a new 52-week high at $447.28, roughly 55% above its October lows, highlighting strong investor momentum and demand for the stock. Amgen Reaches a New 52-Week High
• Positive Sentiment: Amgen and AstraZeneca reported Phase III Tezspire data in eosinophilic esophagitis, a potential expansion opportunity for the drug and a catalyst for the companies’ respiratory-immunology portfolios. Amgen and AstraZeneca Report Phase III Tezspire Data
• Positive Sentiment: Recent fundamentals remain supportive: Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Its diversified oncology, rare-disease, and inflammation portfolio also provides a steadier cash-flow profile than some high-growth biotech peers.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last three months. Insiders own 0.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AMGN. Barclays raised their price objective on shares of Amgen from $380.00 to $400.00 and gave the company an "equal weight" rating in a report on Wednesday. Weiss Ratings raised shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 8th. Canaccord Genuity Group upped their price target on shares of Amgen from $366.00 to $384.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. TD Cowen upped their price target on shares of Amgen from $420.00 to $452.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Finally, Mizuho raised their price target on shares of Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $388.64.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.